Navigation Links
pectoris in Medical News

AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available

...ation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infraction have occurred. The dosage should ...OPROL-XL. In clinical trials of patients with hypertension and angina pectoris the most common adverse events reported with immediate-release metoprolol t...

Different treatment options in chronic coronary artery disease

...verview to the analyses of registries, which provide complementary data. Thus PCI or ACB is advisable in those patients who still suffer from angina pectoris under drug treatment or for whom relevant ischemia has been demonstrated by non-invasive methods. According to the authors, the main indication for ao...

University of the Basque Country team develop nano-hydrogels capable of detecting cancer cells

...y short time , but very large molecules cannot be injected because they may cause obstruction or problems on the organism such as, for example, angina pectoris and even heart attack. The essential condition for their use in humans is that these particles have to be sufficiently small so as not to obstruct the...

Global Economic Meltdown - Is the European Cardiac Rhythm Management Market Spared?

...he heart due to CVD affects the conduction system of the heart. Depending on the level of malfunction, the manifestation of outcome varies from angina pectoris to ventricular arrhythmia. Demographics such as the increasing baby-boomer population, sedentary lifestyle, and increased disorders such as obe...

Effectiveness Of Drug-Releasing Coronary Stents

... two drugs, which were used to coat stents in patients with new coronary artery lesions. The trial called REALITY examined 1,386 patients with angina pectoris in 90 hospitals in Europe, Latin America, and Asia between August 2003 and February 2004. The patients were randomly assigned either a sirolimus-relea...

Nifedipine Found To Effective For Patients With Angina

... Angina pectoris is the most common symptom in patients with plaque build-up in their coronary artery. A recent study shows the heart medication // nifedipine (Adalat ...
pectoris in Medical Technology

Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics' Heart Health Test

... accounting for nearly 30-percent of all deaths. Cardiovascular disease has a number of forms but the most common are myocardial infarction and angina pectoris which affect the heart itself. There are well known environmental risk factors associated with cardiovascular disease such as smoking, diet, inactivit...

Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)

...ded release should avoid abrupt cessation of therapy. Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, is some cases, myocardial infarction have occurred. The dosage should be reduced gradually over a one-to-two-week period, and the patient should ...

Coronary Artery Disease ARISE Trial Showed AGI-1067 Did Not Meet Primary Endpoint

...endpoint of CV death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, use of coronary revascularisation and for angina pectoris with objective evidence of ischemia. AstraZeneca and AtheroGenics will now work together to fully analyse the full data set for AGI-1067, including ...

Calcium Channel Blocker Adalat GITS Offer Additional Benefits

...ris. Lowering blood pressure helps reduce stroke and heart failure The ACTION-trial showed that adding nifedipine GITS to a best practice angina pectoris therapy significantly reduced the incidence of any stroke or TIA (28%) and the development of new overt heart failure (29%). Using an innovative stati...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

...panese patients. In addition to its impact on overall cardiovascular events and stroke, Diovan demonstrated relative reductions of 65% in angina pectoris (recurring acute chest pain), 46% in heart failure and 81% in aortic dissection (separation of the wall layers in the body's main artery) compared to ...

Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study

...t; FONT-FAMILY: Sabon">In addition to its impact on overall cardiovascular events and stroke, Diovan demonstrated relative reductions of 65% in angina pectoris (recurring acute chest pain), 47% in heart failure and 81% in aortic dissection (separation of the wall layers in the body’s main artery) compar...
pectoris in Medical Definition

Angor animi

... Angor animi (also referred to as angina animi [1] [2] , Gairdner's disease [2] and also angina pectoris sine dolore [2] ), is a term used in medicine to describe a person's perception that they are in fact dying. Most cases of angor animi are ...

Pathology

...tensive heart disease - Hypertensive nephropathy - Secondary hypertension - Renovascular hypertension Ischaemic heart disease Angina pectoris - Prinzmetal's angina - Myocardial infarction - Dressler's syndrome Pulmonary circulation Pulmonary embolism - Cor pulmonale ...
pectoris in Medical Dictionary

Angina pectoris

Angina pectoris , commonly known as angina , is severe chest pain due to ischemia of the heart muscle, generally due to obstruction or spasm of the coronary arteries . Coronary artery disease, the main cause of angina , is due to atherosclerosis of the cardiac arteries.... Fe...

Unstable angina

... coronary ... Unstable angina occurs in approximately 6 out of every 10,000 people. ... Angina literally means choking pain, and angina pectoris refers to a painful or ... Unstable angina comes on when a person is resting, asleep, or undergoes physical ... Your doctor will probably dia...

Coronary artery spasm

...about coronary artery spasm . ... spasm briefly narrows the coronary artery , ... Coronary artery spasm causes a rare type of angina pectoris called variant ... The coronary arteries are the blood vessels that supply blood to the heart muscle. Sometimes one of them can go into s...

Angina

...e angina should be considered a ... Angina pectoris is a Latin phrase that means "strangling in the ch...gina literally means choking pain, and angina pectoris refers to a painful or ... Stable angina typical...ng-term outlook, complications, risks ... Angina pectoris is Latin for squeezing of the chest. ... If yo...
pectoris in Biological Technology

CV Therapeutics' Board of Directors Rejects Astellas' Tender Offer

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug devel...

CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug devel...

CV Therapeutics' Board of Directors Rejects Astellas Unsolicited Proposal

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug devel...

CV Therapeutics Reports 2008 Fourth Quarter and Full Year Financial Results

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug devel...

CV Therapeutics Statement on Unsolicited Proposal From Astellas

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug devel...

CV Therapeutics Reports 2008 Third Quarter Financial Results

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal therapies. CV Therapeutics also has other clinical and preclinical drug devel...

FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c

...add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal th...add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti anginal th...

CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. CV Therapeutics also has other clinical and preclinical drug develo...

CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008

...ne prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. CV Therapeutics also has other clinical and preclinical drug develo...

CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group

...R) (ranolazine prolonged release tablets) is approved for use in Europe as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. Ranexa is approved for use in 375 mg, 500 mg and 750 mg doses, admi...
Other Tags
(Date:9/30/2014)... HealthDay Reporter MONDAY, Sept. ... medical implants -- artificial valves, hip replacements, surgical mesh and ... before or after their approval by the U.S. Food and ... conducted by prominent nonprofit groups and published online Sept. 29 ... for inadequate medical device testing on lax oversight by the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Houstonians seeking ... a place to visit on the Internet. Paul ... Houston’s most respected cosmetic surgeons, has launched a new ... the benefits of Botox Cosmetic services. The ... , According to the new website, Botox Cosmetic ...
(Date:9/30/2014)... September 30, 2014 Neuromuscular and ... throughout the United States and worldwide. It is ... are diagnosed each year, adding to the more ... disease. Approximately 400,000 people in the US are ... Add to these statistics the 2.4 percent of ...
(Date:9/30/2014)... Los Angeles, CA (PRWEB) September 30, 2014 ... Farnoosh is now offering gum depigmentation treatments for dark ... but they can make people feel extremely self-conscious about ... treat discolored or dark gums. “I am one of ... lightening , and I have treated celebrities, business leaders, ...
(Date:9/30/2014)... Herceptin is the best drug treatment for a type ... standard of care for that type of tumor, according ... HER2-positive breast cancers tend to be more aggressive than ... Clinic. For the study, more than 8,300 patients ... (lapatinib) in addition to standard chemotherapy. After 4.5 ...
Breaking Medicine News(10 mins):Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 2Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 3Health News:Medical Implant Devices Skate Through Review Process, Studies Claim 4Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2
(Date:9/30/2014)... HONG KONG , Sept. 30, 2014 Winners of ... The Economist Events, Innovation Summit scheduled to take place at the ... At the summit, the award winners will share their experiences and ... people who have made a proven innovation over the past decade, ... the night before the summit. It will be the ...
(Date:9/29/2014)... A new study confirms that the exposure to tar ... than of regular cigarettes. Similarly, exposure to nicotine ... increasingly popular type of cigarette in several countries around ... of certain toxic chemicals in the smoke of these ... because lower levels of chemicals in the smoke are ...
(Date:9/29/2014)... Monday, September 29: Between 1970 and 2010 ... around the globe dropped 52 percent, says the ... Wildlife Fund (WWF). This biodiversity loss occurs disproportionately ... use of high-income countries. , In addition to ... data point to other warning signs about the ...
Breaking Biology News(10 mins):Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7Slim cigarette smokers not exposed to more harmful chemicals 2Half of global wildlife lost, says new WWF report 2
Other Contents